Last reviewed · How we verify
NCT03918070: YuChooSeR
Observatory to Assess the Yukon Choice PC & the Yukon Chrome PC Sirolimus Eluting Bioabsorbable Polymer Stents Systems
trial testing Yukon Choice PC and Yukon Chrome PC in Coronaropathy in 2,722 participants. Participants enrolled and being followed up; not accepting new ones.
24 April 2024
Quick facts
| Lead sponsor | Translumina GmbH |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 2,722 |
| Start date | 17 April 2019 |
| Primary completion | 24 April 2024 |
| Estimated completion | 24 May 2024 |
| Sites | 19 locations across France |
Drugs / interventions tested
- Yukon Choice PC and Yukon Chrome PC
Conditions studied
- Coronaropathy — all drugs for Coronaropathy →
Sponsor
Translumina GmbH
Who can join
18 and older, any sex, with Coronaropathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The TRANSLUMINA GmbH YuChooSeR Observatory is a prospective, multicentric post-marketing observatory designed to evaluate large scale safety and reliability of the Yukon Choice PC and the Yukon Chrome PC stents systems use in routine, clinical practice. This based observatory will enroll 3000 patients to 30 sites in France.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03918070
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Translumina GmbH trials
Trials by the same sponsor.
- NCT06420505 — Evaluation of the Vivo Isar Stent System in Routine Clinical Practice · recruiting
- NCT05703646 — Safety and Clinical Performance of the Yukon Choice PC, Yukon Chrome PC & Yukon Choice Flex Stents in Routine Practice · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03918070 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Translumina GmbH
- Last refreshed: 8 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03918070.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing